Schizophrenia: Epidemiology, Causes, Neurobiology, Pathophysiology, and Treatment

Adams, D. D., Knight, J. G., & Ebringer, A. (2012). The autoimmune model of schizophrenia. ISRN Psychiatry, 2012, 758072. https://doi.org/10.5402/2012/758072

Agarwal, V., Abhijnhan, A., & Raviraj, P. (2007). Ayurvedic medicine for schizophrenia. The Cochrane Database of Systematic Reviews, 4, CD006867. https://doi.org/10.1002/14651858.CD006867

Agbeli, M. O. (2020). Reducing antipsychotic medication use in long-term care settings (2020-04052-126; Issues 5-A). ProQuest Information & Learning.

Akhtar, S., & Volkan, V. D. (2005). Mental zoo: Animals in the human mind and its pathology. International Universities Press.

Albert, N., Randers, L., Allott, K., Jensen, H. D., Melau, M., Hjorthøj, C., & Nordentoft, M. (2019). Cognitive functioning following discontinuation of antipsychotic medication A naturalistic sub-group analysis from the OPUS II trial. Psychological Medicine, 49(7), 1138–1147. https://doi.org/10.1017/S0033291718001836

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5 (5 edition). American Psychiatric Publishing.

Angyal, A. (1950). The psychodynamic process of illness and recovery in a case of catatonic schizophrenia. Psychiatry: Journal for the Study of Interpersonal Processes, 13, 149–165.

Arnaiz, A., Zumárraga, M., Díez-Altuna, I., Uriarte, J. J., Moro, J., & Pérez-Ansorena, M. A. (2011). Oral health and the symptoms of schizophrenia. Psychiatry Research, 188(1), 24–28. https://doi.org/10.1016/j.psychres.2010.09.012

Ashcroft, K., Kingdon, D. G., & Chadwick, P. (2012). Persecutory delusions and childhood emotional abuse in people with a diagnosis of schizophrenia. Psychosis: Psychological, Social and Integrative Approaches, 4(2), 168–171. https://doi.org/10.1080/17522439.2011.619012

Azrin, S. T., Goldstein, A. B., & Heinssen, R. K. (2015). Early intervention for psychosis: The Recovery After an Initial Schizophrenia Episode project. Psychiatric Annals, 45(11), 548–553. https://doi.org/10.3928/00485713-20151103-05

B, S., & Tk, C. (2014). Role of C-reactive protein in schizophrenia: An overview. Psychiatry Research, 216(2), 277–285. https://doi.org/10.1016/j.psychres.2014.02.004

Barkan, T., Peled, A., Modai, I., Barak, P., Weizman, A., & Rehavi, M. (2006). Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients. European Neuropsychopharmacology, 16(8), 572–579. https://doi.org/10.1016/j.euroneuro.2006.03.001

Barrowclough, C., Haddock, G., Lobban, F., Jones, S., Siddle, R., Roberts, C., & Gregg, L. (2006). Group cognitive-behavioural therapy for schizophrenia. British Journal of Psychiatry, 189(6), 527–532. https://doi.org/10.1192/bjp.bp.106.021386

Baumeister, A. A., & Francis, J. L. (2002). Historical development of the dopamine hypothesis of schizophrenia. Journal of the History of the Neurosciences, 11(3), 265–277. https://doi.org/10.1076/jhin.11.3.265.10391

Beraki, S., Aronsson, F., Karlsson, H., Ögren, S. O., & Kristensson, K. (2005). Influenza A virus infection causes alterations in expression of synaptic regulatory genes combined with changes in cognitive and emotional behaviors in mice. Molecular Psychiatry, 10(3), 299–308. https://doi.org/10.1038/sj.mp.4001545

Bhugra, D. (2000). Migration and schizophrenia. Acta Psychiatrica Scandinavica, 102, 68–73. https://doi.org/10.1034/j.1600-0447.2000.00015.x

Bonnigal-Katz, D. (2019). Psychosis Therapy Project: A psychoanalytic project in the community. British Journal of Psychotherapy, 35(4), 586–589. https://doi.org/10.1111/bjp.12466

Boydell, J., Van Os, J., Lambri, M., Castle, D., Allardyce, J., McCreadie, R. G., & Murray, R. M. (2003). Incidence of schizophrenia in south-east London between 1965 and 1997. British Journal of Psychiatry, 182(1), 45–49. https://doi.org/10.1192/bjp.182.1.45

Brakoulias, V., Starcevic, V., Albert, U., Arumugham, S. S., Bailey, B. E., Belloch, A., Borda, T., Dell’Osso, L., Elias, J. A., Falkenstein, M. J., Ferrao, Y. A., Fontenelle, L. F., Jelinek, L., Kalogeraki, L., Kay, B., Laurito, L. D., Lochner, C., Maina, G., Marazziti, D., … Fineberg, N. A. (2019). Treatments used for obsessive-compulsive disorder-An international perspective. Human Psychopharmacology, 34(1), e2686. https://doi.org/10.1002/hup.2686

Brambilla, P., & Tansella, M. (2007). Can neuroimaging studies help us in understanding the biological causes of schizophrenia? International Review of Psychiatry, 19(4), 313–314. https://doi.org/10.1080/09540260701507954

Braslow, J. T. (1999). History and evidence-based medicine: Lessons from the history of somatic treatments from the 1900s to the 1950s. Mental Health Services Research, 1(4), 231–240. https://doi.org/10.1023/a:1022325508430

Bray, I., Waraich, P., Jones, W., Slater, S., Goldner, E. M., & Somers, J. (2006). Increase in schizophrenia incidence rates: Findings in a Canadian cohort born 1975-1985. Social Psychiatry and Psychiatric Epidemiology, 41(8), 611–618. https://doi.org/10.1007/s00127-006-0073-z

Bresnahan, M., Menezes, P., Varma, V., & Susser, E. (2003). Geographical variation in incidence, course and outcome of schizophrenia: A comparison of developing and developed countries. The Epidemiology of Schizophrenia., 18–33.

Brown, A. S., & McGrath, J. J. (2011). The Prevention of Schizophrenia. Schizophrenia Bulletin, 37(2), 257–261. https://doi.org/10.1093/schbul/sbq122

Brown, A. S., & Patterson, P. H. (2011). Maternal Infection and Schizophrenia: Implications for Prevention. Schizophrenia Bulletin, 37(2), 284–290. https://doi.org/10.1093/schbul/sbq146

Brown, A. S., Schaefer, C. A., Quesenberry, C. P. Jr., Shen, L., & Susser, E. S. (2006). No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? American Journal of Psychiatry, 163(12), 2178–2180. https://doi.org/10.1176/appi.ajp.163.12.2178

Brown, S., Inskip, H., & Barraclough, B. (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212–217. https://doi.org/10.1192/bjp.177.3.212

Buckley, L., & Pettit, T. (2007). Supportive therapy for schizophrenia. Schizophrenia Bulletin, 33(4), 859–860. https://doi.org/10.1093/schbul/sbm058

Buka, S. L., Cannon, T. D., Torrey, E. F., & Yolken, R. H. (2008). Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biological Psychiatry, 63(8), 809–815.

Burns, J. (2007). The Descent of Madness: Evolutionary Origins of Psychosis and the Social Brain (1 edition). Routledge.

Butler, P. D., Susser, E. S., Brown, A. S., Kaufmann, C. A., & Gorman, J. M. (1994). Prenatal nutritional deprivation as a risk factor in schizophrenia: Preclinical evidence. Neuropsychopharmacology, 11(4), 227–235. https://doi.org/10.1038/sj.npp.1380109

Byrne, M., Agerbo, E., Bennedsen, B., Eaton, W. W., & Mortensen, P. B. (2007). Obstetric conditions and risk of first admission with schizophrenia: A Danish national register based study. Schizophrenia Research, 97(1), 51–59. https://doi.org/10.1016/j.schres.2007.07.018

Capasso, R. M., Lineberry, T. W., Bostwick, J. M., Decker, P. A., & St. Sauver, J. (2008). Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950-2005. Schizophrenia Research, 98(1), 287–294. https://doi.org/10.1016/j.schres.2007.10.005

Caruso, J. P., & Sheehan, J. P. (2017). Psychosurgery, ethics, and media: A history of Walter Freeman and the lobotomy. Neurosurgical Focus, 43(3), E6. https://doi.org/10.3171/2017.6.FOCUS17257

Casey, D. E., Haupt, D. W., Newcomer, J. W., Henderson, D. C., Sernyak, M. J., Davidson, M., Lindenmayer, J.-P., Manoukian, S. V., Banerji, M. A., Lebovitz, H. E., & Hennekens, C. H. (2004). Antipsychotic-lnduced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients with Schizophrenia. Journal of Clinical Psychiatry, 65, 4–18.

Castle, D. J., & Morgan, V. (2008). Epidemiology. Clinical Handbook of Schizophrenia., 14–24.

Chan, S. K. W., Hui, C. L. M., Chang, W. C., Lee, E. H. M., & Chen, E. Y. H. (2019). Ten-year follow up of patients with first-episode schizophrenia spectrum disorder from an early intervention service: Predictors of clinical remission and functional recovery. Schizophrenia Research, 204, 65–71. https://doi.org/10.1016/j.schres.2018.08.022

Chaudhry, I. B., Husain, N., ur Rahman, R., Husain, M. O., Hamirani, M. M., Kazmi, A., Baig, S., Haddad, P. M., Buch, M. H., Qureshi, I., Mehmood, N., Kiran, T., Fu, B., Afsar, S., & Deakin, B. (2015). A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: Study protocol for a randomised controlled trial. Trials, 16, 9. https://doi.org/10.1186/1745-6215-16-9

Cheniaux, E., Landeira-Fernandez, J., Telles, L. L., Lessa, J. L. M., Dias, A., Duncan, T., & Versiani, M. (2008). Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood. Journal of Affective Disorders, 106(3), 209–217. https://doi.org/10.1016/j.jad.2007.07.009

Chiu, V. W., Ree, M., Janca, A., Iyyalol, R., Dragovic, M., & Waters, F. (2018). Sleep profiles and CBT-I response in schizophrenia and related psychoses. Psychiatry Research, 268, 279–287. https://doi.org/10.1016/j.psychres.2018.07.027

Chwastiak, L. A., & Tek, C. (2009). The unchanging mortality gap for people with schizophrenia. The Lancet, 374(9690), 590–592. https://doi.org/10.1016/S0140-6736(09)61072-2

Cowan, H. R. (2020). Is schizophrenia research relevant during the COVID-19 pandemic? Schizophrenia Research. https://doi.org/10.1016/j.schres.2020.04.002

Cullen, A. E., Holmes, S., Pollak, T. A., Blackman, G., Joyce, D. W., Kempton, M. J., Murray, R. M., McGuire, P., & Mondelli, V. (2019). Associations Between Non-neurological Autoimmune Disorders and Psychosis: A Meta-analysis. Biological Psychiatry, 85(1), 35–48. https://doi.org/10.1016/j.biopsych.2018.06.016

Dalman, C., Allebeck, P., Gunnell, D., Harrison, G., Kristensson, K., Lewis, G., Lofving, S., Rasmussen, F., Wicks, S., & Karlsson, H. (2008). Infections in the CNS during childhood and the risk of subsequent psychotic illness: A cohort study of more than one million Swedish subjects. American Journal of Psychiatry, 165(1), 59–65. https://doi.org/10.1176/appi.ajp.2007.07050740

D’Astous, M., Cottin, S., Roy, M., Picard, C., & Cantin, L. (2013). Bilateral stereotactic anterior capsulotomy for obsessive-compulsive disorder: Long-term follow-up. Journal of Neurology, Neurosurgery, and Psychiatry, 84(11), 1208–1213. https://doi.org/10.1136/jnnp-2012-303826

Davenport, S., Hobson, R., & Margison, F. (2000). Treatment development in psychodynamic-interpersonal psychotherapy (Hobson’s ’Conversational Model’) for chronic treatment resistant schizophrenia: Two single case studies. British Journal of Psychotherapy, 16(3), 287–302. https://doi.org/10.1111/j.1752-0118.2000.tb00520.x

Davis, J. M., & Leucht, S. (2008). Has research informed us on the practical drug treatment of schizophrenia? Schizophrenia Bulletin, 34(3), 403–405. https://doi.org/10.1093/schbul/sbn011

De Luca, V., Zai, G., Tharmalingam, S., de Bartolomeis, A., Wong, G., & Kennedy, J. L. (2006). Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behaviour in schizophrenia. European Neuropsychopharmacology, 16(4), 268–271. https://doi.org/10.1016/j.euroneuro.2005.09.007

De Masi, F. (2020). Psychosis and analytic therapy: A complex relationship. The International Journal of Psychoanalysis, 101(1), 152–168. https://doi.org/10.1080/00207578.2020.1716626

Dean, B., Hussain, T., Scarr, E., Pavey, G., & Copolov, D. L. (2001). Extended treatment with typical and atypical antipsychotic drugs: Differential effects on the densities of dopamine D-sub-2-like and GABA-sub(A) receptors in rat striatum. Life Sciences, 69(11), 1257–1268. https://doi.org/10.1016/S0024-3205(01)01214-0

Dean, B., Pavey, G., Thomas, D., & Scarr, E. (2006). Cortical serotonin-sub(7, 1D) and -sub(1F) receptors: Effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophrenia Research, 88(1), 265–274. https://doi.org/10.1016/j.schres.2006.07.003

Dean, K., Bramon, E., & Murray, R. M. (2003). The causes of schizophrenia: Neurodevelopment and other risk factors. Journal of Psychiatric Practice, 9(6), 442–454. https://doi.org/10.1097/00131746-200311000-00007

Dickerson, F., Boronow, J., Stallings, C., Origoni, A., & Yolken, R. (2007). Toxoplasma gondii in individuals with schizophrenia: Association with clinical and demographic factors and with mortality. Schizophrenia Bulletin, 33(3), 737–740. https://doi.org/10.1093/schbul/sbm005

Dickerson, F., Kirkpatrick, B., Boronow, J., Stallings, C., Origoni, A., & Yolken, R. (2006). Deficit schizophrenia: Association with serum antibodies to cytomegalovirus. Schizophrenia Bulletin, 32(2), 396–400. https://doi.org/10.1093/schbul/sbi054

Dickerson, F., Severance, E., & Yolken, R. (2017). The microbiome, immunity, and schizophrenia and bipolar disorder. Brain, Behavior, and Immunity, 62, 46–52. https://doi.org/10.1016/j.bbi.2016.12.010

Dickson, H., Hedges, E. P., Ma, S. Y., Cullen, A. E., MacCabe, J. H., Kempton, M. J., Downs, J., & Laurens, K. R. (2020). Academic achievement and schizophrenia: A systematic meta-analysis. Psychological Medicine. https://doi.org/10.1017/S0033291720002354

Dion, G. L., & Dellario, D. (1988). Symptom subtypes in persons institutionalized with schizophrenia: Comparison of demographics, outcome and functional skills. Rehabilitation Psychology, 33(2), 95–104. https://doi.org/10.1037/h0091684

Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014). Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Research International, 2014, 656370. https://doi.org/10.1155/2014/656370

dosReis, S., Johnson, E., Steinwachs, D., Rohde, C., Skinner, E. A., Fahey, M., & Lehman, A. F. (2008). Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia. Schizophrenia Research, 101(1), 304–311. https://doi.org/10.1016/j.schres.2007.12.475

Downing, D. L., & Mills, J. (2018). Outpatient Treatment of Psychosis: Psychodynamic Approaches to Evidence-Based Practice. Routledge. https://doi.org/10.4324/9780429478123

Dully, H., & Fleming, C. (2007). My Lobotomy. Crown.

Dykxhoorn, J., Hollander, A.-C., Lewis, G., Magnusson, C., Dalman, C., & Kirkbride, J. B. (2019). Risk of schizophrenia, schizoaffective, and bipolar disorders by migrant status, region of origin, and age-at-migration: A national cohort study of 18 million people. Psychological Medicine, 49(14), 2354–2363. https://doi.org/10.1017/S0033291718003227

Eecke, W. V. (2019). How Does Psychoanalysis Work with Persons Afflicted By Schizophrenia? Journal of Psychology & Psychotherapy, 9(5), 1–5. https://doi.org/10.35248/2161-0487.19.9.367

Enger, C., Weatherby, L., Reynolds, R. F., Glasser, D. B., & Walker, A. M. (2004). Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia. Journal of Nervous and Mental Disease, 192(1), 19–27. https://doi.org/10.1097/01.nmd.0000105996.62105.07

Fairbairn, W. R. D. (1941). A revised psychopathology of the psychoses and psychoneuroses. The International Journal of Psychoanalysis, 22, 250–270.

Fakra, E., Salgado-Pineda, P., Delaveau, P., Hariri, A. R., & Blin, O. (2008). Neural bases of different cognitive strategies for facial affect processing in schizophrenia. Schizophrenia Research, 100(1), 191–205. https://doi.org/10.1016/j.schres.2007.11.040

Fan, J. B., & Sklar, P. (2005). Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Molecular Psychiatry, 10(10), 928–938. https://doi.org/10.1038/sj.mp.4001690

Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Huang, H., Oishi, K., Mori, S., Smee, D. F., Pearce, D. A., Winter, C., Sohr, R., & Juckel, G. (2008). Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: Implications for genesis of neurodevelopmental disorders. Schizophrenia Research, 99(1), 56–70. https://doi.org/10.1016/j.schres.2007.11.018

Fearon, P., Kirkbride, J. B., Morgan, C., Dazzan, P., Morgan, K., Lloyd, T., Hutchinson, G., Tarrant, J., Fung, W. L. A., Holloway, J., Mallett, R., Harrison, G., Leff, J., Jones, P. B., & Murray, R. M. (2006). Incidence of schizophrenia and other psychoses in ethnic minority groups: Results from the MRC AESOP Study. Psychological Medicine, 36(11), 1541–1550. https://doi.org/10.1017/S0033291706008774

Ferenczi, S., & Jones, E. (1916). Some Clinical Observations on Paranoia and Paraphrenia. In Contributions to psycho-analysis. (2006-03526-011; pp. 238–249). Richard G. Badger. https://doi.org/10.1037/10925-011

Findlay, L. J. (2015). Decision-making processes and health behaviors among adults diagnosed with schizophrenia(2015-99060-062; Issues 9-B(E)). ProQuest Information & Learning.

Flegr, J., & Kuba, R. (2016). The relation of Toxoplasma infection and sexual attraction to fear, danger, pain, and submissiveness. Evolutionary Psychology, 14(3). https://doi.org/10.1177/1474704916659746

Fonseca, L., Diniz, E., Mendonça, G., Malinowski, F., Mari, J., Gadelha, A., Fonseca, L., Diniz, E., Mendonça, G., Malinowski, F., Mari, J., & Gadelha, A. (2020). Schizophrenia and COVID-19: Risks and recommendations. Brazilian Journal of Psychiatry, AHEAD. https://doi.org/10.1590/1516-4446-2020-0010

Forman, M. (1975). One Flew Over the Cuckoo’s Nest. Warner.

Fornito, A., Yücel, M., Wood, S. J., Adamson, C., Velakoulis, D., Saling, M. M., McGorry, P. D., & Pantelis, C. (2008). Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Human Brain Mapping, 29(4), 478–489. https://doi.org/10.1002/hbm.20412

Fors, B. M., Isacson, D., Bingefors, K., & Widerlöv, B. (2007). Mortality among persons with schizophrenia in Sweden: An epidemiological study. Nordic Journal of Psychiatry, 61(4), 252–259. https://doi.org/10.1080/08039480701414932

Foussias, G., & Remington, G. (2010). Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 55(3), 117–125. https://doi.org/10.1177/070674371005500302

Frankle, W. G., Lombardo, I., Kegeles, L. S., Slifstein, M., Martin, J. H., Huang, Y., Hwang, D.-R., Reich, E., Cangiano, C., Gil, R., Laruelle, M., & Abi-Dargham, A. (2006). Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: A positron emission tomography imaging study with [11C] WAY 100635. Psychopharmacology, 189(2), 155–164. https://doi.org/10.1007/s00213-006-0543-8

Fröhlich, F., & Lustenberger, C. (2020). Neuromodulation of sleep rhythms in schizophrenia: Towards the rational design of non-invasive brain stimulation. Schizophrenia Research. https://doi.org/10.1016/j.schres.2020.04.003

Fromm-Reichmann, F. (1939). Transference problems in schizophrenics. The Psychoanalytic Quarterly, 8, 412–426.

Fu, S., Czajkowski, N., & Torgalsbøen, A.-K. (2019). Cognitive, work, and social outcomes in fully recovered first-episode schizophrenia: On and off antipsychotic medication. Psychiatry: Interpersonal and Biological Processes. https://doi.org/10.1080/00332747.2018.1550735

Garfield, D., & Mackler, D. (2013). Beyond Medication: Therapeutic Engagement and the Recovery from Psychosis. Routledge.

Garver, D. L., Holcomb, J. A., & Christensen, J. D. (2000). Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. Journal of Clinical Psychiatry, 61(12), 964–974.

Gault, J. M., Davis, R., Cascella, N. G., Saks, E. R., Corripio-Collado, I., Anderson, W. S., Olincy, A., Thompson, J. A., Pomarol-Clotet, E., Sawa, A., Daskalakis, Z. J., Lipsman, N., & Abosch, A. (2018). Approaches to neuromodulation for schizophrenia. Journal of Neurology, Neurosurgery & Psychiatry, 89(7), 777–787. https://doi.org/10.1136/jnnp-2017-316946

Gazdag, G., & Ungvari, G. S. (2019). Electroconvulsive therapy: 80 years old and still going strong. World Journal of Psychiatry, 9(1), 1–6. https://doi.org/10.5498/wjp.v9.i1.1

Gearon, J. S., Bellack, A. S., Rachbeisel, J., & Dixon, L. (2001). Drug-use behavior and correlates in people with schizophrenia. Addictive Behaviors, 26(1), 51–61. https://doi.org/10.1016/S0306-4603(00)00084-8

Gibbs, P. L. (2007). The primacy of psychoanalytic intervention in recovery from the psychoses and schizophrenias. The Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 35(2), 287–312.

Gil, A., Gama, C. S., de Jesus, D. R., Lobato, M. I., Zimmer, M., & Belmonte-de-Abreu, P. (2009). The association of child abuse and neglect with adult disability in schizophrenia and the prominent role of physical neglect. Child Abuse & Neglect, 33(9), 618–624. https://doi.org/10.1016/j.chiabu.2009.02.006

Gilmore, J. H. (2010). Understanding what causes schizophrenia: A developmental perspective. The American Journal of Psychiatry, 167(1), 8–10. https://doi.org/10.1176/appi.ajp.2009.09111588

Gilmour, G., Dix, S., Fellini, L., Gastambide, F., Plath, N., Steckler, T., Talpos, J., & Tricklebank, M. (2012). NMDA receptors, cognition and schizophrenia – testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology, 62(3), 1401–1412. https://doi.org/10.1016/j.neuropharm.2011.03.015

Giovachinni, P., & Boyer, B. L. (1980). Psychoanalytic Treatment of Schizophrenic Borderline and Characterological Disorders(Enlarged 2nd Edition). Jason Aronson, Inc.

Girdler, S. J., Confino, J. E., & Woesner, M. E. (2019). Exercise as a Treatment for Schizophrenia: A Review. Psychopharmacology Bulletin, 49(1), 56–69.

Gold, C. (2015). Dose and effect in CBT for schizophrenia. The British Journal of Psychiatry, 207(3), 269–273. https://doi.org/10.1192/bjp.207.3.269

González de Chávez, M. (2009). Treatment of psychoses before the twentieth century. In Y. O. Alanen, M. González de Chávez, A.-L. S. Silver, & B. Martindale (Eds.), Psychotherapeutic approaches to schizophrenic psychoses: Past, present and future. (2009-10328-002; pp. 10–22). Routledge/Taylor & Francis Group.

Gonzalez-Flores, B. L. (2020). Impact of independent exercise on recovery, well-being, and motivation among individuals with schizophrenia (2020-28121-043; Issues 4-B). ProQuest Information & Learning.

Gottdiener, W. H. (2006). Individual psychodynamic psychotherapy of schizophrenia: Empirical evidence for the practicing clinician. Psychoanalytic Psychology, 23(3), 583–589. https://doi.org/10.1037/0736-9735.23.3.583

Gray, L., Scarr, E., & Dean, B. (2006). Serotonin 1a receptor and associated G-protein activation schizophrenia and bipolar disorder. Psychiatry Research, 143(2), 111–120. https://doi.org/10.1016/j.psychres.2005.09.010

Green, M. F., Horan, W. P., & Lee, J. (2019). Nonsocial and social cognition in schizophrenia: Current evidence and future directions. World Psychiatry, 18(2), 146–161. https://doi.org/10.1002/wps.20624

Grignon, S., & Trottier, M. (2005). Capgras Syndrome in the Modern Era: Self Misidentification on an ID Picture. The Canadian Journal of Psychiatry / La Revue Canadienne de Psychiatrie, 50(1), 74–75.

Grotstein, J. S. (2001). A rationale for the psychoanalytically informed psychotherapy of schizophrenia and other psychoses: Towards the concept of “rehabilitative psychoanalysis.” A Language for Psychosis: Psychoanalysis of Psychotic States., 9–26.

Grotstein, J. S. (2003). Towards the concept of “rehabilitative psychoanalytic psychotherapy” in the treatment of schizophrenia. Preventive Strategies for Schizophrenic Disorders: Basic Principles, Opportunities and Limits., 350–365.

Gründer, G., & Cumming, P. (2016). The dopamine hypothesis of schizophrenia: Current status. In T. Abel & T. Nickl-Jockschat (Eds.), The neurobiology of schizophrenia. (2016-43112-007; pp. 109–124). Elsevier Academic Press. https://doi.org/10.1016/B978-0-12-801829-3.00015-X

Gur, R. E., Loughead, J., Kohler, C. G., Elliott, M. A., Lesko, K., Ruparel, K., Wolf, D. H., Bilker, W. B., & Gur, R. C. (2007). Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Archives of General Psychiatry, 64(12), 1356–1366. https://doi.org/10.1001/archpsyc.64.12.1356

Hadar, R., Bikovski, L., Soto-Montenegro, M. L., Schimke, J., Maier, P., Ewing, S., Voget, M., Wieske, F., Götz, T., Desco, M., Hamani, C., Pascau, J., Weiner, I., & Winter, C. (2018). Early neuromodulation prevents the development of brain and behavioral abnormalities in a rodent model of schizophrenia. Molecular Psychiatry, 23(4), 943–951. https://doi.org/10.1038/mp.2017.52

Hagiwara, H., Fujita, Y., Ishima, T., Kunitachi, S., Shirayama, Y., Iyo, M., & Hashimoto, K. (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: Role of serotonin 5-HT-sub(1A) receptors. European Neuropsychopharmacology, 18(6), 448–454. https://doi.org/10.1016/j.euroneuro.2007.11.005

Hashimoto, T., Bazmi, H. H., Mirnics, K., Wu, Q., Sampson, A. R., & Lewis, D. A. (2008). Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. American Journal of Psychiatry, 165(4), 479–489. https://doi.org/10.1176/appi.ajp.2007.07081223

Healy, D. (2006). Neuroleptics and mortality: A 50-year cycle: Invited commentary on... schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188(2), 128. https://doi.org/10.1192/bjp.bp.105.018911

Hendrick, I. (1928). Encephalitis lethargica and the interpretation of mental disease. American Journal of Psychiatry, 7, 989–1014.

Henssler, J., Brandt, L., Müller, M., Liu, S., Montag, C., Sterzer, P., & Heinz, A. (2020). Migration and schizophrenia: Meta-analysis and explanatory framework. European Archives of Psychiatry and Clinical Neuroscience, 270(3), 325–335. https://doi.org/10.1007/s00406-019-01028-7

Hoeffding, L. K., Rosengren, A., Thygesen, J. H., Schmock, H., Werge, T., & Hansen, T. (2017). Evaluation of shared genetic susceptibility loci between autoimmune diseases and schizophrenia based on genome-wide association studies. Nordic Journal of Psychiatry, 71(1), 20–25. https://doi.org/10.1080/08039488.2016.1198420

Hong, J., & Bang, M. (2020). Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing. Clinical Psychopharmacology and Neuroscience, 18(1), 10–24. https://doi.org/10.9758/cpn.2020.18.1.10

Høyersten, J. G. (1996). [Possessed! Some historical, psychiatric and curent moments of demonic possession]. Tidsskrift for Den Norske Laegeforening: Tidsskrift for Praktisk Medicin, Ny Raekke, 116(30), 3602–3606.

Hua, M., Peng, Y., Zhou, Y., Qin, W., Yu, C., & Liang, M. (2020). Disrupted pathways from limbic areas to thalamus in schizophrenia highlighted by whole-brain resting-state effective connectivity analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 99, 109837. https://doi.org/10.1016/j.pnpbp.2019.109837

İpçi, K., Yildiz, M., İncedere, A., Kiras, F., Esen, D., & Gürcan, M. B. (2020). Subjective recovery in patients with schizophrenia and related factors. Community Mental Health Journal. https://doi.org/10.1007/s10597-020-00616-5

Janssen, I., Krabbendam, L., Bak, M., Hanssen, M., Vollebergh, W., de Graaf, R., & van Os, J. (2004). Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatrica Scandinavica, 109(1), 38–45. https://doi.org/10.1046/j.0001-690X.2003.00217.x

Jauhar, S., McKenna, P. J., Radua, J., Fung, E., Salvador, R., & Laws, K. R. (2014). Cognitive-behavioural therapy for the symptoms of schizophrenia: Systematic review and meta-analysis with examination of potential bias. The British Journal of Psychiatry, 204(1), 20–29. https://doi.org/10.1192/bjp.bp.112.116285

Jentsch, J. D., & Roth, R. H. (1999). The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 20(3), 201–225. https://doi.org/10.1016/S0893-133X(98)00060-8

Jia, J., Shen, J., Liu, F.-H., Wong, H. K., Yang, X.-J., Wu, Q.-J., Zhang, H., Wang, H.-N., Tan, Q.-R., & Zhang, Z.-J. (2019). Effectiveness of electroacupuncture and electroconvulsive therapy as additional treatment in hospitalized patients with schizophrenia: A retrospective controlled study. Frontiers in Psychology, 10. https://doi.org/10.3389/fpsyg.2019.02306

Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188(2), 122–127. https://doi.org/10.1192/bjp.188.2.122

Joyal, C. C., Hallé, P., Lapierre, D., & Hodgins, S. (2003). Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophrenia Research, 63(3), 297–299. https://doi.org/10.1016/S0920-9964(02)00387-0

Juckel, G., & Hoffmann, K. (2018). [The Indian Ayurveda medicine-a meaningful supplement to psychiatric treatment?]. Der Nervenarzt, 89(9), 999–1008. https://doi.org/10.1007/s00115-018-0538-9

Jung, C. G. (1925). The content of the psychoses. In J. S. Van Teslaar (Ed.), An outline of psychoanalysis.(2006-21557-012; pp. 255–271). Modern Library. https://doi.org/10.1037/11350-012

Kane, J. M., & Leucht, S. (2008). Unanswered questions in schizophrenia clinical trials. Schizophrenia Bulletin, 34(2), 302–309. https://doi.org/10.1093/schbul/sbm143

Kapelski, P., Hauser, J., Dmitrzak-Weglarz, M., Skibinska, M., Slopien, A., Kaczmarkiewicz-Fass, M., Rajewska, A., Gattner, K., & Czerski, P. M. (2006). Brak asocjacji pomiedzy polimorfizmem insercyjno-delecyjnym promotorowego odcinka genu transportera serotoniny a schizofrenia. Psychiatria Polska, 40(5), 925–935.

Kapsambelis, V. (2019). Psychoanalytic approaches to psychotic disorders in a public mental health system. British Journal of Psychotherapy, 35(4), 577–585. https://doi.org/10.1111/bjp.12482

Kelly, D. L., Rowland, L. M., Patchan, K. M., Sullivan, K., Earl, A., Raley, H., Liu, F., Feldman, S., & McMahon, R. P. (2016). Schizophrenia clinical symptom differences in women vs men with and without a history of childhood physical abuse. Child and Adolescent Psychiatry and Mental Health, 10. https://doi.org/10.1186/s13034-016-0092-9

Kesey, K. (1963). One Flew Over the Cuckoo’s Nest. Berkley.

Khandaker, G. M., Zimbron, J., Dalman, C., Lewis, G., & Jones, P. B. (2012). Childhood infection and adult schizophrenia: A meta-analysis of population-based studies. Schizophrenia Research, 139(1–3), 161–168. https://doi.org/10.1016/j.schres.2012.05.023

Kim, H., Kim, D., & Kim, S. H. (2018). Association of types of delusions and hallucinations with childhood abuse and neglect among inpatients with schizophrenia in South Korea: A preliminary study. Psychosis: Psychological, Social and Integrative Approaches, 10(3), 208–212. https://doi.org/10.1080/17522439.2018.1472627

Kline, J., Becker, J., & Giese, C. (1992). Psychodynamic interventions revisited: Options for the treatment of schizophrenia. Psychotherapy: Theory, Research, Practice, Training, 29(3), 366–377. https://doi.org/10.1037/h0088538

Knight, J. G. (1982). Dopamine-receptor-stimulating autoantibodies: A possible cause of schizophrenia. Lancet (London, England), 2(8307), 1073–1076. https://doi.org/10.1016/s0140-6736(82)90007-1

Knight, J. G., Menkes, D. B., Highton, J., & Adams, D. D. (2007). Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Molecular Psychiatry, 12(5), 424–431.

Koch, E., Rosenthal, B., Lundquist, A., Chen, C.-H., & Kauppi, K. (2020). Interactome overlap between schizophrenia and cognition. Schizophrenia Research, S0920996420303467. https://doi.org/10.1016/j.schres.2020.06.002

Kohler, C. G., Loughead, J., Ruparel, K., Indersmitten, T., Barrett, F. S., Gur, R. E., & Gur, R. C. (2008). Brain activation during eye gaze discrimination in stable schizophrenia. Schizophrenia Research, 99(1), 286–293. https://doi.org/10.1016/j.schres.2007.09.038

Kortegaard, H. M. (1993). Music therapy in the psychodynamic treatment of schizophrenia. Music Therapy in Health and Education., 55–65.

Kozloff, N., Mulsant, B. H., Stergiopoulos, V., & Voineskos, A. N. (2020). The COVID-19 Global Pandemic: Implications for People with Schizophrenia and Related Disorders. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaa051

Krogmann, A., Peters, L., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019). Keeping up with the therapeutic advances in schizophrenia: A review of novel and emerging pharmacological entities. CNS Spectrums, 24(S1), 38–69. https://doi.org/10.1017/S109285291900124X

Kroll, J. L. (2007). New directions in the conceptualization of psychotic disorders. Current Opinion in Psychiatry, 20(6), 573–577.

Kumar, V., Vajawat, B., & Rao, N. P. (2020). Frontal gaba in schizophrenia: A meta-analysis of 1h-mrs studies. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622975.2020.1731925

Lamster, F., Kiener, J., Wagner, K., Rief, W., Görge, S. C., Iwaniuk, S., Leube, D., Falkenberg, I., Kluge, I., Kircher, T., & Mehl, S. (2018). Ist Wahn indirekt veränderbar? Ein stimmungsverbesserndes Konzept der kognitive Verhaltenstherapie für die stationäre Standardversorgung von Patienten mit schizophrenen Störungen = Are delusions indirectly alterable? A mood-stabilizing CBT-p concept for inpatients with schizophrenia. Verhaltenstherapie, 28(3), 138–146. https://doi.org/10.1159/000486966

Laskemoen, J. F., Büchmann, C., Barrett, E. A., Collier-Høegh, M., Haatveit, B., Vedal, T. J., Ueland, T., Melle, I., Aas, M., & Simonsen, C. (2020). Do sleep disturbances contribute to cognitive impairments in schizophrenia spectrum and bipolar disorders? European Archives of Psychiatry and Clinical Neuroscience, 270(6), 749–759. https://doi.org/10.1007/s00406-019-01075-0

Laursen, T. M. (2019). Causes of premature mortality in schizophrenia: A review of literature published in 2018. Current Opinion in Psychiatry, 32(5), 388–393. https://doi.org/10.1097/YCO.0000000000000530

Laursen, T. M., Munk-Olsena, T., & Vestergaardb, M. (2012). Life expectancy and cardiovascular mortality in persons with schizophrenia. Current Opinion in Psychiatry, 25(2), 83–88. https://doi.org/10.1097/YCO.0b013e32835035ca

Lawrence, R., Bradshaw, T., & Mairs, H. (2006). Group cognitive behavioural therapy for schizophrenia: A systematic review of the literature. Journal of Psychiatric and Mental Health Nursing, 13(6), 673–681. https://doi.org/10.1111/j.1365-2850.2006.01014.x

Leão, T. S., Sundquist, J., Frank, G., Johansson, L.-M., Johansson, S.-E., & Sundquist, K. (2006). Incidence of schizophrenia or other psychoses in first-and second-generation immigrants: A national cohort study. Journal of Nervous and Mental Disease, 194(1), 27–33. https://doi.org/10.1097/01.nmd.0000195312.81334.81

Leonhardt, B. L., Hamm, J. A., Belanger, E. A., & Lysaker, P. H. (2015). Childhood sexual abuse moderates the relationship of self-reflectivity with increased emotional distress in schizophrenia. Psychosis: Psychological, Social and Integrative Approaches, 7(3), 195–205. https://doi.org/10.1080/17522439.2014.968858

Lester, D. (2007). Suicide mortality in schizophrenics. Suicide in Schizophrenia., 19–29.

Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007). Physical illness and schizophrenia: A review of the literature. Acta Psychiatrica Scandinavica, 116(5), 317–333. https://doi.org/10.1111/j.1600-0447.2007.01095.x

Lewis, S., & Lieberman, J. (2008). CATIE and CutLASS: Can we handle the truth? British Journal of Psychiatry, 192(3), 161–163. https://doi.org/10.1192/bjp.bp.107.037218

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, john K. (2005). Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine, 353(12), 1209–1223. https://doi.org/10.1056/NEJMoa051688

López-Muñoz, F., Alamo, C., Cuenca, E., Shen, W. W., Clervoy, P., & Rubio, G. (2005). History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists, 17(3), 113–135. https://doi.org/10.1080/10401230591002002

Lorenzo, C. V., Baca-Garcia, E., Diaz-Hernandez, M., Botillo-Martin, C., Perez-Rodriguez, M. M., Fernandez-Ramos, C., Saiz-Gonzalez, M. D., Quintero-Gutierrez, F. J., Saiz-Ruiz, J., Piqueras, J. F., de Rivera, J. L. G., & de Leon, J. (2006). Association between the T102C polymorphism of the serotonin-2A receptor gene and schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30(6), 1136–1138. https://doi.org/10.1016/j.pnpbp.2006.04.027

Lublin, H., & Eberhard, J. (2008). Content versus delivery: Challenges and options in the treatment of schizophrenia. European Neuropsychopharmacology, 18(3), v–vi. https://doi.org/10.1016/j.euroneuro.2008.04.001

Lucas, R. (2003). The relationship between psychoanalysis and schizophrenia. International Journal of Psychoanalysis, 84(1), 3–9. https://doi.org/10.1516/00207570360509439

Lysaker, P. H., Beattie, N. L., Strasburger, A. M., & Davis, L. W. (2005). Reported history of child sexual abuse in schizophrenia: Associations with heightened symptom levels and poorer participation over four months in vocational rehabilitation. Journal of Nervous and Mental Disease, 193(12), 790–795. https://doi.org/10.1097/01.nmd.0000188970.11916.76

Lysaker, P. H., Meyer, P. S., Evans, J. D., Clements, C. A., & Marks, K. A. (2001). Childhood Sexual Trauma and Psychosocial Functioning in Adults with Schizophrenia. Psychiatric Services, 52(11), 1485–1488. https://doi.org/10.1176/appi.ps.52.11.1485

Lysaker, P. H., Nees, M. A., Lancaster, R. S., & Davis, L. W. (2004). Vocational function among persons with schizophrenia with and without history of childhood sexual trauma. Journal of Traumatic Stress, 17(5), 435–438. https://doi.org/10.1023/B:JOTS.0000048957.70768.b9

Marneros, A. (2007). Do schizoaffective disorders exist at all? Acta Psychiatrica Scandinavica, 115(2), 162. https://doi.org/10.1111/j.1600-0447.2006.00945.x

Masciotra, L., Landreau, F., Conesa, H. A., & Erausquin, G. A. de. (2005). Pathophysiology of Schizophrenia: A New Look at the Role of Dopamine. Trends in Schizophrenia Research., 27–44.

Maurel, M., Belzeaux, R., Adida, M., Fakra, E., Cermolacce, M., Da Fonseca, D., & Azorin, J.-M. (2011). Schizophrénie, cognition et psycho-éducation = Schizophrenia, cognition and psychoeducation. L’Encéphale: Revue de Psychiatrie Clinique Biologique et Thérapeutique, 37(Suppl 2), S151–S154. https://doi.org/10.1016/S0013-7006(11)70043-4

May, P. (1968). Treatment of schizophrenia; A comparative study of five treatment methods (First Edition edition). Science House.

McGrath, J., Brown, A., & St Clair, D. (2011). Prevention and Schizophrenia—The Role of Dietary Factors. Schizophrenia Bulletin, 37(2), 272–283. https://doi.org/10.1093/schbul/sbq121

McGrath, J. J. (2006). Variations in the incidence of schizophrenia: Data versus dogma. Schizophrenia Bulletin, 32(1), 195–197. https://doi.org/10.1093/schbul/sbi052

Meyer, U., Murray, P. J., Urwyler, A., Yee, B. K., Schedlowski, M., & Feldon, J. (2008). Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Molecular Psychiatry, 13(2), 208–221. https://doi.org/10.1038/sj.mp.4002042

Meyer, Urs, Feldon, J., Schedlowski, M., & Yee, B. K. (2006). Immunological stress at the maternal-foetal interface: A link between neurodevelopment and adult psychopathology. Brain, Behavior, and Immunity, 20(4), 378–388. https://doi.org/10.1016/j.bbi.2005.11.003

Meyer, Urs, Nyffeler, M., Schwendener, S., Knuesel, I., Yee, B. K., & Feldon, J. (2008). Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology, 33(2), 441–456. https://doi.org/10.1038/sj.npp.1301413

Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects. Biological Psychiatry, 70(7), 663–671. https://doi.org/10.1016/j.biopsych.2011.04.013

Miller, P., Lawrie, S. M., Hodges, A., Clafferty, R., Cosway, R., & Johnstone, E. C. (2001). Genetic liability, illicit drug use, life stress and psychotic symptoms: Preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Social Psychiatry and Psychiatric Epidemiology, 36(7), 338–342. https://doi.org/10.1007/s001270170038

Mishra, A., Mishra, A. K., & Jha, S. (2018). Effect of traditional medicine brahmi vati and bacoside A-rich fraction of Bacopa monnieri on acute pentylenetetrzole-induced seizures, amphetamine-induced model of schizophrenia, and scopolamine-induced memory loss in laboratory animals. Epilepsy & Behavior: E&B, 80, 144–151. https://doi.org/10.1016/j.yebeh.2017.12.040

Mitsadali, I., Grayson, B., Idris, N. F., Watson, L., Burgess, M., & Neill, J. (2020). Aerobic exercise improves memory and prevents cognitive deficits of relevance to schizophrenia in an animal model. Journal of Psychopharmacology, 34(7), 695–708. https://doi.org/10.1177/0269881120922963

Mittal, V. A., Saczawa, M. E., Walker, E., Willhite, R., & Walder, D. (2008). Prenatal exposure to viral infection and conversion among adolescents at high-risk for psychotic disorders. Schizophrenia Research, 99(1), 375–376. https://doi.org/10.1016/j.schres.2007.11.037

Møllerhøj, J., Os Stølan, L., Erdner, A., Hedberg, B., Stahl, K., Riise, J., Jedenius, E., & Rise, M. B. (2019). ’i live, I don’t work, but I live a very normal life’—A qualitative interview study of scandinavian user experiences of schizophrenia, antipsychotic medication, and personal recovery processes. Perspectives in Psychiatric Care. https://doi.org/10.1111/ppc.12444

Moran, E. K., Gold, J. M., Carter, C. S., MacDonald, A. W., Ragland, J. D., Silverstein, S. M., Luck, S. J., & Barch, D. M. (2020). Both unmedicated and medicated individuals with schizophrenia show impairments across a wide array of cognitive and reinforcement learning tasks. Psychological Medicine. https://doi.org/10.1017/S003329172000286X

Moreno, J. L., Kurita, M., Holloway, T., López, J., Cadagan, R., Martínez-Sobrido, L., García-Sastre, A., & González-Maeso, J. (2011). Maternal influenza viral infection causes schizophrenia- like alterations of 5-HT2A and mGlu₂ receptors in the adult offspring. The Journal of Neuroscience, 31(5), 1863–1872. https://doi.org/10.1523/JNEUROSCI.4230-10.2011

Mueser, K. T., & Berenbaum, H. (1990). Psychodynamic treatment of schizophrenia: Is there a future? Psychological Medicine, 20(2), 253–262.

Mullen, P. E. (2005). Child sexual abuse and schizophrenia: Author’s reply. The British Journal of Psychiatry, 186(1), 76–76.

Murray, R. M., Grech, A., Phillips, P., & Johnson, S. (2003). What is the relationship between substance abuse and schizophrenia? In R. M. Murray, P. B. Jones, E. Susser, J. van Os, & M. Cannon (Eds.), The epidemiology of schizophrenia. (2003-04863-016; pp. 317–342). Cambridge University Press.

Nelson, C. L. M., Amsbaugh, H. M., Reilly, J. L., Rosen, C., Marvin, R. W., Ragozzino, M. E., Bishop, J. R., Sweeney, J. A., & Hill, S. K. (2018). Beneficial and adverse effects of antipsychotic medication on cognitive flexibility are related to COMT genotype in first episode psychosis. Schizophrenia Research, 202, 212–216. https://doi.org/10.1016/j.schres.2018.06.029

Niebuhr, D. W., Millikan, A. M., Cowan, D. N., Yolken, R., Li, Y., & Weber, N. S. (2008). Selected infectious agents and risk of schizophrenia among U.S. Military personnel. American Journal of Psychiatry, 165(1), 99–106. https://doi.org/10.1176/appi.ajp.2007.06081254

Nightingale, L. C., & McQueeney, D. A. (1996). Group therapy for schizophrenia: Combining and expanding the psychoeducational model with supportive psychotherapy. International Journal of Group Psychotherapy, 46(4), 517–533.

Nixon, N. L., & Doody, G. A. (2005). Official psychiatric morbidity and the incidence of schizophrenia 1881-1994. Psychological Medicine, 35(8), 1145–1153. https://doi.org/10.1017/S0033291705004939

Ohara, K. (2007). The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 31(2), 469–474. https://doi.org/10.1016/j.pnpbp.2006.11.013

Ortiz-Medina, M. B., Perea, M., Torales, J., Ventriglio, A., Vitrani, G., Aguilar, L., & Roncero, C. (2018). Cannabis consumption and psychosis or schizophrenia development. International Journal of Social Psychiatry, 64(7), 690–704. https://doi.org/10.1177/0020764018801690

Ottet, M.-C., Schaer, M., Cammoun, L., Schneider, M., Debbané, M., Thiran, J.-P., & Eliez, S. (2013). Reduced fronto-temporal and limbic connectivity in the 22q112 deletion syndrome: Vulnerability markers for developing schizophrenia? PLoS ONE, 8(3). https://doi.org/10.1371/journal.pone.0058429

Pandurangi, A. K., & Buckley, P. F. (2020). Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia. In G. M. Khandaker, U. Meyer, & P. B. Jones (Eds.), Neuroinflammation and Schizophrenia (pp. 227–244). Springer International Publishing. https://doi.org/10.1007/7854_2019_91

Pang, N., Thrichelvam, N., & Naing, K. O. (2017). Olanzapine-induced Pancytopenia: A Rare but Worrying Complication. East Asian Archives of Psychiatry: Official Journal of the Hong Kong College of Psychiatrists = Dong Ya Jing Shen Ke Xue Zhi: Xianggang Jing Shen Ke Yi Xue Yuan Qi Kan, 27(1), 35–37.

Peltzer, K. (1999). Faith Healing for Mental and Social Disorders in the Northern Province (South Africa). Journal of Religion in Africa, 29(3), 387–402.

Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, E. (2008). Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biological Psychiatry, 63(8), 801–808.

Poulet, E., Brunelin, J., Kallel, L., D’Amato, T., & Saoud, M. (2008). Maintenance treatment with transcranial magnetic stimulation in a patient with late-onset schizophrenia. American Journal of Psychiatry, 165(4), 537–538. https://doi.org/10.1176/appi.ajp.2007.07060868

Prasad, K. M. R., Shirts, B. H., Yolken, R. H., Keshavan, M. S., & Nimgaonkar, V. L. (2007a). Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. Molecular Psychiatry, 12(1), 105–113. https://doi.org/10.1038/sj.mp.4001915

Prasad, K. M. R., Shirts, B. H., Yolken, R. H., Keshavan, M. S., & Nimgaonkar, V. L. (2007b). HSV1 exposure affects prefrontal cortical structure in schizophrenia patients. Molecular Psychiatry, 12(1), 1. https://doi.org/10.1038/sj.mp.4001942

Pratt, L. A. (2012). Characteristics of adults with serious mental illness in the United States household population in 2007. Psychiatric Services, 63(10), 1042–1046. https://doi.org/10.1176/appi.ps.201100442

Rado, J. T., & Hernandez, E. I. (2014). Therapeutic neuromodulation for treatment of schizophrenia. In P. G. Janicak, S. R. Marder, R. Tandon, & M. Goldman (Eds.), Schizophrenia: Recent advances in diagnosis and treatment. (2014-26994-008; pp. 139–160). Springer Science + Business Media.

Rakitzi, S., Georgila, P., & Becker-Woitag, A. P. (2020). The recovery process for individuals with schizophrenia in the context of evidence-based psychotherapy and rehabilitation: A systematic review. European Psychologist. https://doi.org/10.1027/1016-9040/a000400

Ran, M.-S., Chen, E. Y.-H., Conwell, Y., Lai-Wan Chan, C., Yip, P. S. F., Xiang, M.-Z., & Caine, E. D. (2007). Mortality in people with schizophrenia in rural China: 10-year cohort study. British Journal of Psychiatry, 190(3), 237–242. https://doi.org/10.1192/bjp.bp.106.025155

Rashno, M. M., Fallahi, S., Arab-Mazar, Z., & Dana, H. (2019). Seromolecular assess of Toxoplasma gondii infection in pregnant women and neonatal umbilical cord blood. EXCLI Journal, 18, 1–7.

Rathbone, J., Zhang, L., Zhang, M., Xia, J., Liu, X., Yang, Y., & Adams, C. E. (2007). Chinese herbal medicine for schizophrenia: Cochrane systematic review of randomised trials. The British Journal of Psychiatry, 190, 379–384. https://doi.org/10.1192/bjp.bp.106.026880

Read, J., van Os, J., Morrison, A. P., & Ross, C. A. (2005). Childhood trauma, psychosis and schizophrenia: A literature review with theoretical and clinical implications. Acta Psychiatrica Scandinavica, 112(5), 330–350. https://doi.org/10.1111/j.1600-0447.2005.00634.x

Read, John, Agar, K., Argyle, N., & Aderhold, V. (2003). Sexual and physical abuse during childhood and adulthood as predictors of hallucinations, delusions and thought disorder. Psychology and Psychotherapy: Theory, Research and Practice, 76(1), 1–22. https://doi.org/10.1348/14760830260569210

Richard, M. D., & Brahm, N. C. (2012). Schizophrenia and the immune system: Pathophysiology, prevention, and treatment. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 69(9), 757–766. https://doi.org/10.2146/ajhp110271

Robinson, D. S. (2008). Mortality risks and antipsychotics. Primary Psychiatry, 15(4), 21–23.

Rokita, K. I., Dauvermann, M. R., Mothersill, D., Holleran, L., Holland, J., Costello, L., Cullen, C., Kane, R., McKernan, D., Morris, D. W., Kelly, J., Gill, M., Corvin, A., Hallahan, B., McDonald, C., & Donohoe, G. (2020). Childhood trauma, parental bonding, and social cognition in patients with schizophrenia and healthy adults. Journal of Clinical Psychology. https://doi.org/10.1002/jclp.23023

Roser, P. (2019). Cannabis und Schizophrenie—Risikofaktoren, diagnostische Einordnung und Auswirkungen auf Verlauf und Prognose = Cannabis and schizophrenia—Risk factors, diagnostic classification and effects on course and outcome. Forensische Psychiatrie, Psychologie, Kriminologie, 13(3), 225–232. https://doi.org/10.1007/s11757-019-00543-6

Ross, C. (2014). Dissociation in classical texts on schizophrenia. Psychosis: Psychological, Social and Integrative Approaches, 6(4), 342–354. https://doi.org/10.1080/17522439.2013.806570

Ross, C. A. (2006). Dissociation and psychosis: The need for integration of theory and practice. Evolving Psychosis., 238–254.

Rossello, J.-J., Gaillard, G., & Neuilly, M.-T. (2013). Une institution en quête de limites. Le mythe de Tom Sawyer: Un objet transitionnel collectif. = An institution seeking limits. The myth of Tom Sawyer : A collective transitional object. Revue de Psychothérapie Psychanalytique de Groupe, 60, 141–152. https://doi.org/10.3917/rppg.060.0141

Ryan, J. E., Veliz, P., McCabe, S. E., Stoddard, S. A., & Boyd, C. J. (2020). Association of early onset of cannabis, cigarette, other drug use and schizophrenia or psychosis. Schizophrenia Research, 215, 482–484. https://doi.org/10.1016/j.schres.2019.10.002

Sabe, M., Kaiser, S., & Sentissi, O. (2020). Physical exercise for negative symptoms of schizophrenia: Systematic review of randomized controlled trials and meta-analysis. General Hospital Psychiatry, 62, 13–20. https://doi.org/10.1016/j.genhosppsych.2019.11.002

Saha, S., Chant, D. C., Welham, J. L., & McGrath, J. J. (2006). The incidence and prevalence of schizophrenia varies with latitude. Acta Psychiatrica Scandinavica, 114(1), 36–39. https://doi.org/10.1111/j.1600-0447.2005.00742.x

Saha, S., Chant, D., & McGrath, J. (2007). A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Archives of General Psychiatry, 64(10), 1123–1131. https://doi.org/10.1001/archpsyc.64.10.1123

Saha, S., Welham, J., Chant, D., & McGrath, J. (2006). Incidence of schizophrenia does not vary with economic status of the country: Evidence from a systematic review. Social Psychiatry and Psychiatric Epidemiology, 41(5), 338–340. https://doi.org/10.1007/s00127-006-0041-7

Sarter, M., Nelson, C. L., & Bruno, J. P. (2005). Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia. Schizophrenia Bulletin, 31(1), 117–138. https://doi.org/10.1093/schbul/sbi006

Schürhoff, F., Laguerre, A., Fisher, H., Etain, B., Méary, A., Soussy, C., Szöke, A., & Leboyer, M. (2009). Self-reported childhood trauma correlates with schizotypal measures in schizophrenia but not bipolar pedigrees. Psychological Medicine, 39(3), 365–370. https://doi.org/10.1017/S0033291708003905

Schwab, S. G., & Wildenauer, D. B. (2008). Research on causes for schizophrenia: Are we close? Schizophrenia Research, 102(1), 29–30. https://doi.org/10.1016/j.schres.2008.04.005

Scull, A. (2005). Madhouse: A Tragic Tale of Megalomania and Modern Medicine (1st ed.). Yale University Press.

Searles, H. F. (1986). Collected Papers on Schizophrenia and Related Subjects (1 edition). Routledge.

Seeman, P. (2000). Antipsychotic drugs, dopamine D2 receptors, and schizophrenia. Neurotransmitter Receptors in Actions of Antipsychotic Medications., 43–63.

Sepehry, A. A., Potvin, S., Élie, R., & Stip, E. (2007). Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: A meta-analysis. Journal of Clinical Psychiatry, 68(4), 604–610.

Setién‐Suero, E., Neergaard, K., Ortiz‐García de la Foz, V., Suárez‐Pinilla, P., Martínez‐García, O., Crespo‐Facorro, B., & Ayesa‐Arriola, R. (2019). Stopping cannabis use benefits outcome in psychosis: Findings from 10‐year follow‐up study in the PAFIP‐cohort. Acta Psychiatrica Scandinavica, 140(4), 349–359. https://doi.org/10.1111/acps.13081

Severance, E. G., Prandovszky, E., Castiglione, J., & Yolken, R. H. (2015). Gastroenterology issues in schizophrenia: Why the gut matters. Current Psychiatry Reports, 17(5), 27. https://doi.org/10.1007/s11920-015-0574-0

Severance, E. G., & Yolken, R. H. (2020). From Infection to the Microbiome: An Evolving Role of Microbes in Schizophrenia. Current Topics in Behavioral Neurosciences, 44, 67–84. https://doi.org/10.1007/7854_2018_84

Severance, E. G., Yolken, R. H., & Eaton, W. W. (2016). Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: More than a gut feeling. Schizophrenia Research, 176(1), 23–35. https://doi.org/10.1016/j.schres.2014.06.027

Shekunov, J. (2016). Immigration and Risk of Psychiatric Disorders: A Review of Existing Literature. American Journal of Psychiatry Residents’ Journal, 11(2), 3–5. https://doi.org/10.1176/appi.ajp-rj.2016.110202

Shimada, T., Ito, S., Makabe, A., Yamanushi, A., Takenaka, A., & Kobayashi, M. (2019). Aerobic exercise and cognitive functioning in schizophrenia: A pilot randomized controlled trial. Psychiatry Research, 282. https://doi.org/10.1016/j.psychres.2019.112638

Shonin, E., Van Gordon, W., & Griffiths, M. D. (2014). Cognitive behavioral therapy (CBT) and Meditation Awareness Training (MAT) for the treatment of co-occurring schizophrenia and pathological gambling: A case study. International Journal of Mental Health and Addiction, 12(2), 181–196. https://doi.org/10.1007/s11469-013-9460-3

Silva, M. A., & Restrepo, D. (2019). Recuperación funcional en la esquizofrenia = Functional recovery in schizophrenia. Revista Colombiana de Psiquiatría, 48(4), 252–260. https://doi.org/10.1016/j.rcp.2017.08.004

Sim, K., Chan, Y. H., Chua, T. H., Mahendran, R., Chong, S. A., & McGorry, P. (2006). Physical comorbidity, insight, quality of life and global functioning in first episode schizophrenia: A 24-month, longitudinal outcome study. Schizophrenia Research, 88(1), 82–89. https://doi.org/10.1016/j.schres.2006.07.004

Sim, K., Chua, T. H., Chan, Y. H., Mahendran, R., & Chong, S. A. (2006). Psychiatric comorbidity in first episode schizophrenia: A 2 year, longitudinal outcome study. Journal of Psychiatric Research, 40(7), 656–663. https://doi.org/10.1016/j.jpsychires.2006.06.008

Simeone, J. C., Ward, A. J., Rotella, P., Collins, J., & Windisch, R. (2015). An evaluation of variation in published estimates of schizophrenia prevalence from 1990-2013: A systematic literature review. BMC Psychiatry, 15(1), 1–14. https://doi.org/10.1186/s12888-015-0578-7

Sommer, I. E., de Witte, L., Begemann, M., & Kahn, R. S. (2012). Nonsteroidal anti-inflammatory drugs in schizophrenia: Ready for practice or a good start? A meta-analysis. The Journal of Clinical Psychiatry, 73(4), 414–419. https://doi.org/10.4088/JCP.10r06823

Spataro, J., Mullen, P. E., Burgess, P. M., Wells, D. L., & Moss, S. A. (2004). Impact of child sexual abuse on mental health: Prospective study in males and females. The British Journal of Psychiatry, 184(5), 416–421. https://doi.org/10.1192/bjp.184.5.416

Staudt, M. D., Herring, E. Z., Gao, K., Miller, J. P., & Sweet, J. A. (2019). Evolution in the Treatment of Psychiatric Disorders: From Psychosurgery to Psychopharmacology to Neuromodulation. Frontiers in Neuroscience, 13. https://doi.org/10.3389/fnins.2019.00108

Steel, C. (2013). CBT for schizophrenia: Evidence-based interventions and future directions (C. Steel, Ed.; 2013-04591-000). Wiley Blackwell. https://doi.org/10.1002/9781118330029

Stone, M. H. (1999). The History of the Psychoanalytic Treatment of Schizophrenia. J. Amer. Acad. Psychoanal., 583–601.

Sudak, D. M. (2004). Cognitive-behavioral therapy for schizophrenia. Journal of Psychiatric Practice, 10(5), 331–333. https://doi.org/10.1097/00131746-200409000-00007

Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertugrul, A., & Meltzer, H. Y. (2007). Effect of buspirone, a serotonin-sub(1A) partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophrenia Research, 95(1), 158–168. https://doi.org/10.1016/j.schres.2007.06.008

Sutterland, A. L., Kuin, A., Kuiper, B., van Gool, T., Leboyer, M., Fond, G., & de Haan, L. (2019). Driving us mad: The association of Toxoplasma gondii with suicide attempts and traffic accidents—A systematic review and meta-analysis. Psychological Medicine, 49(10), 1608–1623. https://doi.org/10.1017/S0033291719000813

Suvisaari, J. M., Haukka, J. K., Tanskanen, A. J., & Lönnqvist, J. K. (1999). Decline in the incidence of schizophrenia in Finnish cohorts born from 1954 to 1965. Archives of General Psychiatry, 56(8), 733–740. https://doi.org/10.1001/archpsyc.56.8.733

Szumlinski, K. K., & Kippin, T. E. (2008). Homer: A genetic factor in schizophrenia? Cortical Deficits in Schizophrenia: From Genes to Function., 29–72.

Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010). Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. Schizophrenia Research, 122(1), 1–23. https://doi.org/10.1016/j.schres.2010.05.025

Thomann, P. A., Wolf, R. C., Nolte, H. M., Hirjak, D., Hofer, S., Seidl, U., Depping, M. S., Stieltjes, B., Maier-Hein, K., Sambataro, F., & Wüstenberg, T. (2017). Neuromodulation in response to electroconvulsive therapy in schizophrenia and major depression. Brain Stimulation, 10(3), 637–644. https://doi.org/10.1016/j.brs.2017.01.578

Tidd, C. W. (1937). Increasing reality acceptance by a schizoid personality during analysis. Bulletin of the Menninger Clinic, 1, 176–183.

Tidd, C. W. (1938). A note on the treatment of schizophrenia. Bulletin of the Menninger Clinic, 2, 89–93.

Tochigi, M., Okazaki, Y., Kato, N., & Sasaki, T. (2004). What causes seasonality of birth in schizophrenia? Neuroscience Research, 48(1), 1–11. https://doi.org/10.1016/j.neures.2003.09.002

Torrey, E. F., Bartko, J. J., & Yolken, R. H. (2012). Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update. Schizophrenia Bulletin, 38(3), 642–647. https://doi.org/10.1093/schbul/sbs043

Trudeau, K. J., Burtner, J., Villapiano, A. J., Jones, M., Butler, S. F., & Joshi, K. (2018). Burden of schizophrenia or psychosis-related symptoms in adults undergoing substance abuse evaluation. Journal of Nervous and Mental Disease, 206(7), 528–536.

Tsapakis, E.-M., Guillin, O., & Murray, R. M. (2003). Does dopamine sensitization underlie the association between schizophrenia and drug abuse? Current Opinion in Psychiatry, 16, S45-s52. https://doi.org/10.1097/00001504-200304002-00008

Turkington, D., Dudley, R., Warman, D. M., & Beck, A. T. (2004). Cognitive-behavioral therapy for schizophrenia: A review. Journal of Psychiatric Practice, 10(1), 5–16. https://doi.org/10.1097/00131746-200401000-00002

Turkington, D., Kingdon, D., & Chadwick, P. (2003). Cognitive-behavioural therapy for schizophrenia: Filling the therapeutic vacuum. British Journal of Psychiatry, 183(2), 98–99. https://doi.org/10.1192/bjp.183.2.98

Valon, P. (2020). Gisela Pankow (1914–1998): Towards a psychoanalytic treatment of the psychoses. The International Journal of Psychoanalysis, 101(1), 169–185. https://doi.org/10.1080/00207578.2020.1716628

Vaucher, J., Keating, B. J., Lasserre, A. M., Gan, W., Lyall, D. M., Ward, J., Smith, D. J., Pell, J. P., Sattar, N., Paré, G., & Holmes, M. V. (2018). Cannabis use and risk of schizophrenia: A Mendelian randomization study. Molecular Psychiatry, 23(5), 1287–1292. https://doi.org/10.1038/mp.2016.252

Vidal, S., & Huguelet, P. (2019). Thérapie cognitive basée sur le concept de rétablissement pour la schizophrénie: Un cas clinique = Recovery Oriented Cognitive Therapy for schizophrenia: A case report. Journal de Thérapie Comportementale et Cognitive, 29(2), 57–66. https://doi.org/10.1016/j.jtcc.2018.11.001

Vogel, M., Meier, J., Grönke, S., Waage, M., Schneider, W., Freyberger, H. J., & Klauer, T. (2011). Differential effects of childhood abuse and neglect: Mediation by posttraumatic distress in neurotic disorder and negative symptoms in schizophrenia? Psychiatry Research, 189(1), 121–127. https://doi.org/10.1016/j.psychres.2011.01.008

Volkan, V. D. (2012). Psychoanalytic Technique Expanded: A Textbook on Psychoanalytic Treatment. Pitchstone Publishing.

Volkan, V. D. (1995). The infantile psychotic self and its fates: Understanding and treating schizophrenics and other difficult patients (1995-98163-000). Jason Aronson.

Wang, A. W., Avramopoulos, D., Lori, A., Mulle, J., Conneely, K., Powers, A., Duncan, E., Almli, L., Massa, N., McGrath, J., Schwartz, A. C., Goes, F. S., Weng, L., Wang, R., Yolken, R., Ruczinski, I., Gillespie, C. F., Jovanovic, T., Ressler, K., … Pearce, B. D. (2019). Genome-wide association study in two populations to determine genetic variants associated with Toxoplasma gondii infection and relationship to schizophrenia risk. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 92, 133–147. https://doi.org/10.1016/j.pnpbp.2018.12.019

Wang, L.-Y., Chen, S.-F., Chiang, J.-H., Hsu, C.-Y., & Shen, Y.-C. (2018). Autoimmune diseases are associated with an increased risk of schizophrenia: A nationwide population-based cohort study. Schizophrenia Research, 202, 297–302. https://doi.org/10.1016/j.schres.2018.06.033

Warman, D. M., & Beck, A. T. (2003). Cognitive behavioral therapy for schizophrenia: An overview of treatment. Cognitive and Behavioral Practice, 10(3), 248–254. https://doi.org/10.1016/S1077-7229(03)80037-8

Weininger, B. I. (1938). Psychotherapy during convalescence from psychosis. Psychiatry: Journal for the Study of Interpersonal Processes, 2, 257–264.

Weiser, M., Reichenberg, A., Rabinowitz, J., Kaplan, Z., Caspi, A., Yasvizky, R., Mark, M., Knobler, H. Y., Nahon, D., & Davidson, M. (2003). Self-Reported Drug Abuse in Male Adolescents with Behavioral Disturbances, and Follow-up for Future Schizophrenia. Biological Psychiatry, 54(6), 655–660. https://doi.org/10.1016/S0006-3223(03)00110-0

Whitaker, R. (2002). Mad in America: Bad Science, Bad Medicine, And the Enduring Mistreatment Of The Mentally Ill(1St Edition edition). Basic Books.

White, T., Cullen, K., Rohrer, L. M., Karatekin, C., Luciana, M., Schmidt, M., Hongwanishkul, D., Kumra, S., Schulz, S. C., & Lim, K. O. (2008). Limbic structures and networks in children and adolescents with schizophrenia. Schizophrenia Bulletin, 34(1), 18–29. https://doi.org/10.1093/schbul/sbm110

Williams, L. (Lea) M., Das, P., Liddell, B. J., Olivieri, G., Peduto, A. S., David, A. S., Gordon, E., & Harris, A. W. F. (2007). Fronto-limbic and autonomic disjunctions to negative emotion distinguish schizophrenia subtypes. Psychiatry Research: Neuroimaging, 155(1), 29–44. https://doi.org/10.1016/j.pscychresns.2006.12.018

Winterer, G. (2006). Cortical Microcircuits in Schizophrenia—The Dopamine Hypothesis Revisited. Pharmacopsychiatry, 39, S68-s71. https://doi.org/10.1055/s-2006-931498

Włodarczyk, A., Szarmach, J., Cubała, W. J., & Wiglusz, M. S. (2017). Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy. Psychiatria Danubina, 29(Suppl 3), 345–348.

Wortinger, L. A., Engen, K., Barth, C., Lonning, V., Jørgensen, K. N., Andreassen, O. A., Haukvik, U. K., Vaskinn, A., Ueland, T., & Agartz, I. (2020). Obstetric complications and intelligence in patients on the schizophrenia-bipolar spectrum and healthy participants. Psychological Medicine, 50(11), 1914–1922. https://doi.org/10.1017/S0033291719002046

Wotruba, D., Michels, L., Buechler, R., Metzler, S., Theodoridou, A., Gerstenberg, M., Walitza, S., Kollias, S., Rössler, W., & Heekeren, K. (2014). Aberrant Coupling Within and Across the Default Mode, Task-Positive, and Salience Network in Subjects at Risk for Psychosis. Schizophrenia Bulletin, 40(5), 1095–1104. https://doi.org/10.1093/schbul/sbt161

Xiao, J., Prandovszky, E., Kannan, G., Pletnikov, M. V., Dickerson, F., Severance, E. G., & Yolken, R. H. (2018). Toxoplasma gondii: Biological parameters of the connection to schizophrenia. Schizophrenia Bulletin, 44(5), 983–992. https://doi.org/10.1093/schbul/sby082

Xu, J., He, G., Zhu, J., Zhou, X., St Clair, D., Wang, T., Xiang, Y., Zhao, Q., Xing, Q., Liu, Y., Wang, L., Li, Q., He, L., & Zhao, X. (2015). Prenatal nutritional deficiency reprogrammed postnatal gene expression in mammal brains: Implications for schizophrenia. International Journal of Neuropsychopharmacology, 18(4), 1–9. https://doi.org/10.1093/ijnp/pyu054

Xu, L., Qi, X., Zhu, C., & Wan, L. (2018). Activation of IL-8 and its participation in cancer in schizophrenia patients: New evidence for the autoimmune hypothesis of schizophrenia. Neuropsychiatric Disease and Treatment, 14. https://doi.org/10.2147/NDT.S188210

Xu, X. J., & Jiang, G. S. (2015). Niacin-respondent subset of schizophrenia – a therapeutic review. European Review for Medical and Pharmacological Sciences, 19(6), 988–997.

Zandifar, A., & Badrfam, R. (2020). COVID-19: Considering the prevalence of schizophrenia in the coming decades. Psychiatry Research, 288, 112982. https://doi.org/10.1016/j.psychres.2020.112982

Zhenxing, Y., Longkun, L., & Miaoxin, L. (2018). De novo mutations as causes of schizophrenia. Psychiatry Research, 270, 1168–1169. https://doi.org/10.1016/j.psychres.2018.05.037

Zullino, D. F., Manghi, R., Rathelot, T., Khan, R., & Khazaal, Y. (2010). Cannabis causes schizophrenia? So does nicotine. Addiction Research & Theory, 18(6), 601–605. https://doi.org/10.3109/16066359.2010.489999